The article discusses a global summit of leading glaucoma specialists who gathered to discuss key needs and opportunities in advancing therapies for patients. The summit highlighted the need to advance beyond traditional IOP-lowering therapies and explore new approaches, including innovative drug delivery systems and novel biomarkers.
In a European multicentre trial, 119 schizophrenia patients showed significant improvements in positive and negative symptoms after transitioning to risperidone long-acting injection. The study found that over one-third of patients experienced an improvement of more than 20% in the PANSS total score.
The study found that Tarceva significantly improved overall survival and progression-free survival in patients with advanced NSCLC, with a median survival of 6.7 months compared to 4.7 months in the placebo arm. The treatment also showed improvements in time to symptom deterioration, response rate, and patient survival at one year.
The FDA-approved Avastin increases patient survival by almost five months when combined with chemotherapy, showing a 10.6-month progression-free survival rate compared to 6.2 months in the control group.
A worldwide increase in diabetes is forecasted to lead to a renal disease explosion. FOSRENOL, a new phosphate binding medication, has been shown to be effective in managing hyperphosphataemia, a condition associated with ESRD. The study highlights the need for new treatments to manage serious complications of dialysis.
New global trials build on earlier phase III studies demonstrating FOSRENOL's efficacy in treating hyperphosphataemia. The new trials aim to confirm safety and efficacy of the phosphate binder, which has shown lower incidence of hypercalcaemia compared to calcium-based binders.
FOSRENOL, a lanthanum carbonate-based treatment, has been approved for reducing phosphate risk in dialysis patients with end-stage renal failure. The treatment has shown effectiveness and well-tolerability in studies, improving bone disease outcomes.
A new study demonstrates the benefits of Risperdal Consta in young adults with schizophrenia, improving symptoms and reducing side effects. The treatment showed significant satisfaction and improvement in health-related quality of life, making it a promising option for patients.
A Swedish study found that risperidone long-acting injection reduced hospital admissions by 23% and mean hospital stay duration by 35%. This results in significant cost savings for the healthcare system, with estimates suggesting up to €6,300 per patient annually.
A Phase III study shows that Avastin, an anti-angiogenic agent, extends patient survival time to 20.3 months when added to first-line chemotherapy. The treatment also improves response rates and duration of response across all relevant patient subgroups.
A four-year study found that Risperdal significantly reduces the risk of relapse in schizophrenia patients, with a 42% lower rate compared to haloperidol. Patients taking Risperdal remained relapse-free for an average of over 15 months, whereas those on haloperidol were free for only seven months.
A double-blind study found that Risperdal significantly reduced 'manic' symptoms in patients with bipolar disorder, with treatment response achieved by 48% of patients taking Risperdal. The medication was also shown to improve depressive symptoms and was better tolerated than haloperidol.
A new study shows significant improvements in positive and negative symptoms of schizophrenia when patients are switched to Risperdal Consta without a three-week overlap treatment period. The study found that side effects were mild to moderate, with extrapyramidal symptoms improving significantly by the first month.
A new study found that laparoscopic surgery for gynaecological procedures does not reduce adhesion-related readmissions, with risks comparable to traditional open surgery. The research tracked over 23,000 patients in Scotland and found significant risks of adhesions for many types of laparoscopic procedures.
Phosphate reduction is achieved within a week of treatment with lanthanum carbonate, a new phosphate binder. This effective treatment reduces serum calcium levels and improves cardiovascular health in end-stage renal disease (ESRD) patients.